Genmab — Januar 2018
-
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, forecasts 25 to 30 percent royalty revenue growth in 2018 and potential for royalty revenue to reach nearly $1 billion in 2027 based on the current and expected momentum of partners coformulating products with its ENHANZE
technology. -
or we are betting on a Horse, there is not for sale. Even better in my eyes
-
Hopefully the thing we've got in pibeline is worth a lot more than a potential buyer would offer us within the next half year or so
-
things we've *
-
Brug Google finance. Gratis. Lukkekurser passer og realtidskurser "kun" ca. et sekund forsinket
-
der er da lidt forskel på om de viser 21 point stigning eller kun 16,5. Og så er deres realtidskurser ca 1 minut forsinkede
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind